News
-
Catabasis Initiates Phase 1 Trial Of CAT-2003 For Treatment Of Severe Hypertriglyceridemia
3/26/2013
Catabasis Pharmaceuticals Inc., today announced the initiation of a Phase 1 study to investigate the safety and tolerability of CAT-2003 in healthy volunteers and in adults with mildly elevated lipids. CAT-2003 is a conjugate of niacin and eicosapentaenoic acid (EPA), an omega-3 fatty acid, covalently linked using the company's proprietary SMART Linker technology to create a new chemical entity and is being developed for patients with severe hypertriglyceridemia.
-
Versartis Initiates VERTICAL Trial Of Long Acting Human Growth Hormone In Children With Growth Hormone Deficiency
10/24/2012
Versartis, Inc., an emerging biotechnology company developing novel therapeutics for patients with endocrine disorders, announced today that it has begun its first pediatric clinical trial of VRS-317, the company's proprietary once monthly form of recombinant human growth hormone (rhGH), in children with Growth Hormone Deficiency (GHD). The Versartis Trial In Children to Assess Long-Acting Growth Hormone (VERTICAL) study is being conducted in up to 26 sites in the United States and was initiated following the successful completion of a Phase I study in adults with GHD.
-
Arena Pharmaceuticals Initiates Phase 1 Multiple Dose Clinical Trial Of APD811 For Pulmonary Arterial Hypertension
10/12/2012
Arena Pharmaceuticals, Inc. (NASDAQ: ARNA) announced today the initiation of dosing in a Phase 1 multiple dose clinical trial of APD811, a novel oral drug candidate discovered by Arena that targets the prostacyclin (IP) receptor for the treatment of pulmonary arterial hypertension (PAH).
-
ImmusanT Initiates Clinical Trials Of Nexvax2 Therapeutic Vaccine For Celiac Disease
9/4/2012
ImmusanT announced recently that it has initiated clinical trials in New Zealand, Australia and the U.S. to evaluate Nexvax2, the first therapeutic vaccine for patients with celiac disease.
-
MicuRx Pharmaceuticals Completes Phase 1 Trial For MRX-I, A Next-Generation Antibiotic
4/23/2012
MicuRx Pharmaceuticals, Inc., a privately-held biopharmaceutical company developing next-generation antibiotics, today announced the completion of its Phase 1 clinical trial for MRX-I, its first development-stage antibiotic drug candidate.
-
Achillion Reports Clinical Data On Portfolio Of Protease Inhibitors
1/10/2012
Achillion Pharmaceuticals, Inc. (Nasdaq:ACHN), a leader in the discovery and development of small molecule drugs to combat the most challenging infectious diseases, today reported new clinical trial results on its portfolio of protease inhibitors including: Phase 2 interim 12-week treatment results with ACH-1625 for the treatment of genotype 1 treatment-naive hepatitis C virus (HCV), exploratory data on ACH-1625 for the treatment of HCV genotype 3, and initial proof-of-concept data for ACH-2684.
-
Trident Pharmaceuticals Announces Initiation Of Phase 1a Clinical Study Of HF1020
9/21/2011
Trident Pharmaceuticals Inc., a biotechnology company developing therapies for autoimmune diseases and allergic conditions, today announced the initiation of a Phase 1a study for HF1020, a first in class recombinant protein with immunomodulatory activity.
-
AVI BioPharma Expands Clinical Pipeline With Initiation Of Phase 1 Study Of Influenza Therapeutic Candidate
6/22/2011
AVI BioPharma, Inc. (NASDAQ: AVII), a developer of RNA-based therapeutics, today announced that it initiated dosing of volunteers in a Phase 1 clinical study of AVI-7100, the Company's lead drug candidate for the treatment of influenza.